期刊文献+

慢性乙型肝炎病毒感染者中血清乙型肝炎病毒表面抗原定量检测的临床价值 被引量:6

下载PDF
导出
摘要 目的探讨慢性乙型肝炎病毒(HBV)感染者的乙型肝炎病毒表面抗原(HBsAg)定量检测的临床价值。方法收取HBV感染患者74例,采用化学发光免疫分析法测量血清HBsAg滴度,实时荧光定量PCR检测血清HBV DNA。随访观察进行抗病毒治疗的10例患者的动态检测血清HBsAg滴度。结果 HBe抗原阳性者的HBsAg水平高于阴性者(r=0.002);免疫耐受者的血清HBsAg高于免疫活动者(r=0.03)。血清HBsAg与HBV DNA呈正相关(r=0.61,<0.01),与血清丙氨酸氨基转移酶呈负相关(r=-0.26,r=0.025)。抗病毒治疗完全应答患者的血清HBsAg呈快速下降趋势,而不完全应答的患者的HBsAg下降相对较缓。结论 HBsAg定量值在不同阶段HBV感染者中差异明显,血清HBsAg定量值动态变化可以预测普通干扰素治疗慢性乙型肝炎疗效。
作者 陈飞群 颜展
出处 《现代实用医学》 2014年第2期197-199,共3页 Modern Practical Medicine
  • 相关文献

参考文献5

  • 1Wursthorn K,Lutgehetmann M,Dandri M. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B[J].HEPATOLOGY,2006,(03):675-684.
  • 2贾继东,李兰娟.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24. 被引量:3212
  • 3Cheng J,Imanishi H,Morisaki H. Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line,THP-1[J].Journal of Hepatology,2005,(03):465-471.
  • 4Jonas MM,Block JM,Haber BA. Treatment of children with chronic hepatitis B virus infection in the United States:patient selection and therapeutic options[J].HEPATOLOGY,2010,(06):2192-2205.
  • 5Brunetto MR,Moriconi F,Bonino F. Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B[J].HEPATOLOGY,2009,(04):1141-1150.

二级参考文献15

共引文献3211

同被引文献46

  • 1欧翠华,熊符,陈健文.时间分辨免疫荧光法和电化学发光法检测HBsAg的对比分析[J].江西医学检验,2007,25(2):99-101. 被引量:7
  • 2Korkmaz H,Kesli R,Onder PB,et al. Assessment of evi- dence for positive association and seroprevalenee of hepa- titis B and C in diabetic patients in a developing country [J]. J Invest Med,2015,63(2) :251-257.
  • 3Turhanoglu M,Onur A,Bilman FB,et al. Eight-year sero- prevalence of HBV, HCV and HIV in diyarbakir training and research hospital[J]. Int J Med Sci, 2013, 10 ( 11 ) : 1595-1601.
  • 4Honge BL, Jespersen S, Medina C, et al. Hepatitis C prev- alence among HIV infected patients in Guinea-Bissau~ a descriptive cross-sectional study [J]. Int J Infect Dis, 2014,28(12) :35-40.
  • 5Krawczyk A, Hintze C, Ackermann J, et al. Clinical per formance of the novel DiaSorin LIAISON XL murex: HB- sAg Quant, HCV-Ab, HIV-Ab/Ag assays[J]. J Clin Vir- ol,2014,59(1) :44-49.
  • 6Rezaei M, Nooripoor S, Ghorbani R, et al. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan[ J]. J Prev Med Hyg, 2014, 55 (1) : 1 --3.
  • 7Korkmaz H, Kesli R, OnderPamuk B, et al. Assessment of evi- dence for positive association and seroprevalence of hepatitis B and C in diabetic patients in a developing country [ J ]. J Investig Med, 2015, 63(2) : 251 -257.
  • 8Krawczyk A, Hintze C, Ackermann J, et al. Clinical perform- ance of the novel DiaSorin LIAISON XL murex : HBsAg Quant, HCV - Ab, HIV - Ab/Ag assays [ J]. J ClinVirol, 2014, 59 (1) : 44 -49.
  • 9Turhanoglu M, Onur A, Bilman FB, et al. Eight - year sero- prevalence of HBV, HCV and HIV in Diyarbakir training and re- search hospital[ J]. Int J Med Sci, 2013, 10 (11) : 1595 - 1601.
  • 10Madalifiski K, Kolakowska A, Godzik P. Current views on the persistence of immunity following hepatitis B vaccination [ J ]. PrzeglEpidemiol, 2015, 69( 1): 47-51.

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部